Latest News and Press Releases

Preclinical Data for APVO436 Show Potential Best-in-Class Attributes with Potent T-Cell Directed Tumor Killing and Reduced Cytokine Production Compared to a Competitor Construct Phase 1/1b Clinical...

SEATTLE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that...

Achieves 132% Increase in IXINITY® Quarterly Net Revenue Year-Over-Year More than Doubles Year-to-Date IXINITY Net Revenue from $8.1 Million to $16.7 Million Advances Bispecifics APVO436...

Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses Targets 5T4 Cancer Antigen Present on Many Types of Solid Tumors LUND,...

Plans to Introduce 3000 IU IXINITY Assay for Enhanced Patient Convenience Will Commence Pediatric Study Seeking U.S. Label Expansion Explores Ex-US Licensing and Partnership Collaborations to Expand...

SEATTLE, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that...

Achieves Record IXINITY® Net Revenue with 94% Increase inYear-Over-Year Quarterly Revenue Publishes and Presents New Data on Multiple ADAPTIR™ Bispecific CandidatesShowing Robust Immune System...

Defers Principal Repayments to February 2020 and Reduces Restricted Cash Covenant Aptevo to Announce Second Quarter 2018 Financial Results on August 9, 2018 SEATTLE, Aug. 07, 2018 (GLOBE NEWSWIRE)...

Suppresses Inflammation and Immune Activation Without Lymphocyte Stimulation New Preclinical Data Published in ‘Frontiers in Immunology’ Show APVO210 Holds Promise in the Treatment of Autoimmune...

Almost Doubles Year-Over-Year IXINITY Quarterly Revenue Files IND for APVO436 and Advances APVO210 Toward a Planned Q4 2018 IND Submission Presents Data at AACR Annual Meeting Showing...